Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Carcinomatosis 20Brain Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 8Neoplasm Metastasis 3Lymphoma 3Glioma 3Central Nervous System Neoplasms 3Neoplasms 2Medulloblastoma 2Lung Diseases 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Thoracic Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1Neuropsychological Tests 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Control Groups 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Pemetrexed × CNS × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡